
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Genomics</journal-id><journal-id journal-id-type="iso-abbrev">BMC Genomics</journal-id><journal-title-group><journal-title>BMC Genomics</journal-title></journal-title-group><issn pub-type="epub">1471-2164</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4258300</article-id><article-id pub-id-type="pmid">25418933</article-id><article-id pub-id-type="publisher-id">6720</article-id><article-id pub-id-type="doi">10.1186/1471-2164-15-1015</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Key regulators in prostate cancer identified by co-expression module analysis </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Jiang</surname><given-names>Junfeng</given-names></name><address><email>jf1986.jiang@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Jia</surname><given-names>Peilin</given-names></name><address><email>peilin.jia@vanderbilt.edu</email></address><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhao</surname><given-names>Zhongming</given-names></name><address><email>zhongming.zhao@vanderbilt.edu</email></address><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff3"/><xref ref-type="aff" rid="Aff4"/><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Shen</surname><given-names>Bairong</given-names></name><address><email>bairong.shen@suda.edu.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Center for Systems Biology, Soochow University, Jiangsu, China </aff><aff id="Aff2"><label/>Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN 37203 USA </aff><aff id="Aff3"><label/>Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, TN 37232 USA </aff><aff id="Aff4"><label/>Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37212 USA </aff><aff id="Aff5"><label/>Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN 37232 USA </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>15</volume><elocation-id>1015</elocation-id><history><date date-type="received"><day>8</day><month>7</month><year>2014</year></date><date date-type="accepted"><day>17</day><month>11</month><year>2014</year></date></history><permissions><copyright-statement>© Jiang et al.; licensee BioMed Central Ltd. 2014</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title><text><SENT sid="1" pm="."><plain>Background </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Prostate cancer (PrCa) is the most commonly diagnosed cancer in men in the world. </plain></SENT>
<SENT sid="3" pm="."><plain>Despite the fact that a large number of its genes have been investigated, its etiology remains poorly understood. </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, most PrCa candidate genes have not been rigorously replicated, and the methods by which they biologically function in PrCa remain largely unknown. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="5" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="6" pm="."><plain>Aiming to identify key players in the complex prostate cancer system, we reconstructed PrCa co-expressed modules within functional gene sets defined by the Gene Ontology (GO) annotation (biological process, GO_BP). </plain></SENT>
<SENT sid="7" pm="."><plain>We primarily identified 118 GO_BP terms that were well-preserved between two independent gene expression datasets and a consequent 55 conserved co-expression modules within them. </plain></SENT>
<SENT sid="8" pm="."><plain>Five modules were then found to be significantly enriched with PrCa candidate genes collected from expression Quantitative Trait Loci (eQTL), somatic copy number alteration (SCNA), somatic mutation data, or prognostic analyses. </plain></SENT>
<SENT sid="9" pm="."><plain>Specifically, two transcription factors (TFs) (NFAT and SP1) and three microRNAs (hsa-miR-19a, hsa-miR-15a, and hsa-miR-200b) regulating these five candidate modules were found to be critical to the development of PrCa. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="10" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="11" pm="."><plain>Collectively, our results indicated that genes with similar functions may play important roles in disease through co-expression, and modules with different functions could be regulated by similar genetic components, such as TFs and microRNAs, in a synergistic manner. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="12" pm="."><plain>Electronic supplementary material </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="13" pm="."><plain>The online version of this article (doi:10.1186/1471-2164-15-1015) contains supplementary material, which is available to authorized users. </plain></SENT>
</text></SecTag></p></sec></abstract><SecTag type="KEYWORD"><kwd-group xml:lang="en"><title>Keywords</title><kwd>Prostate cancer</kwd><kwd>Co-expression</kwd><kwd>Gene Ontology</kwd><kwd>Module</kwd><kwd>Transcription factor</kwd><kwd>MicroRNA</kwd></kwd-group></SecTag><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><SecTag type="INTRO"><sec id="Sec1"><title><text><SENT sid="14" pm="."><plain>Background </plain></SENT>
</text></title><p><text><SENT sid="15" pm="."><plain>Prostate cancer (PrCa) is the sixth leading cause of cancer-related deaths of men in the world [1] and the second leading cause in the United States [2]. </plain></SENT>
<SENT sid="16" pm="."><plain>Due to the high risk of metastasis, it has become fundamentally important to uncover the underlying mechanisms of PrCa. </plain></SENT>
<SENT sid="17" pm="."><plain>Factors such as age, ethnicity, family history, heritability, diet, lifestyle, environment, and androgens have long been recognized as contributors to the risk of PrCa [3–5]. </plain></SENT>
<SENT sid="18" pm="."><plain>As demonstrated by twin studies, PrCa’s genetic component is estimated to be as high as 42-57% [6, 7]. </plain></SENT>
</text></p><p><text><SENT sid="19" pm="."><plain>To elucidate the underlying pathophysiology and molecular mechanisms of PrCa, numerous genetic and genomic studies have been conducted, including gene expression profiling [8–12], expression Quantitative Trait Loci (eQTL) mapping [13–15], somatic copy number alteration (SCNA) identification [16], gene mutation detection [17], prognostic gene discovery [18], microRNA (miRNA) expression profiling [14, 19], and transcription factor (TF) enrichment [20], among others. </plain></SENT>
<SENT sid="20" pm="."><plain>The gene expressions profiled by microarray technology have been a major strategy to detect mRNA abundance. </plain></SENT>
<SENT sid="21" pm="."><plain>Traditional, single, and gene-based strategies have been widely applied for gene expression analyses, but they suffered from limitations, such as multiple testing burdens [21], small numbers of differentially expressed genes [22], lack of interactions/regulations among genes [23], or low replication rates [24]. </plain></SENT>
</text></p><p><text><SENT sid="22" pm="."><plain>Alternatively, gene co-expression module analysis attempts to study combined effects by identifying groups of genes that are coordinately expressed [21, 25–27]. </plain></SENT>
<SENT sid="23" pm="."><plain>For instance, Horvath and colleagues have developed a widely used algorithm, the Weighed Gene Co-expression Network Analysis (WGCNA) [28], to search for co-expression modules. </plain></SENT>
<SENT sid="24" pm="."><plain>The R package WGCNA implements a suite of tools for network construction, module detection, module significance examination, module preservation computation, and hub gene query, among many others [29–31]. </plain></SENT>
</text></p><p><text><SENT sid="25" pm="."><plain>To our knowledge, no co-expression module has been constructed for the identification of key regulators in PrCa until now. </plain></SENT>
<SENT sid="26" pm="."><plain>Moreover, traditional co-expression studies that start from whole human genes on a chip (or top differentially expressed genes) often result in very large modules (e.g., &gt;1000 genes). </plain></SENT>
<SENT sid="27" pm="."><plain>Although functional assessments, such as GO enrichment, the functional gene/SNP enrichment test, and hub gene analysis could help to explore the functions of modules, such interpretation typically results in noisy results (e.g., a lot list of GO terms or genes). </plain></SENT>
<SENT sid="28" pm="."><plain>In this study, we developed a framework for gene co-expression module construction in PrCa using the WGCNA approach and augmented by Gene Ontology [32] biological process (GO_BP) annotations. </plain></SENT>
<SENT sid="29" pm="."><plain>We argued that although GO_BP terms are broadly defined for each functional group, there may be subsets of genes in a biological process (GO_BP term) that are coordinately expressed, e.g., in a disease-associated fashion. </plain></SENT>
<SENT sid="30" pm="."><plain>For example, different co-expression modules may underlie different diseases, although they all execute the same biological functions as defined by GO_BP terms. </plain></SENT>
<SENT sid="31" pm="."><plain>To this end, we developed a systematic framework (Figure 1) to search for co-expression modules within each GO_BP term and demonstrated it in PrCa. </plain></SENT>
<SENT sid="32" pm="."><plain>We primarily found 118 preserved GO_BP terms in two PrCa datasets and constructed 55 co-expression modules. </plain></SENT>
<SENT sid="33" pm="."><plain>We then assessed these modules for their enrichment of PrCa candidate genes collected by eQTLs, SCNA, somatic mutation data, or prognostic studies using the hypergeometric test. </plain></SENT>
<SENT sid="34" pm="."><plain>As a result, 5 modules were identified as significantly associated with PrCa, and several TFs and miRNAs were found to be potential key regulators of these candidate modules.Figure 1 Overview of workflow. </plain></SENT>
<SENT sid="35" pm="."><plain>(A) GO-based gene co-expression network construction. </plain></SENT>
<SENT sid="36" pm="."><plain>It has five steps: (1) Raw microarray data processing and analysis. </plain></SENT>
<SENT sid="37" pm="."><plain>(2) GO term expression data matrix-building. </plain></SENT>
<SENT sid="38" pm="."><plain>(3) Pairwise correlation analysis of genes in GO term across different samples. </plain></SENT>
<SENT sid="39" pm="."><plain>(4) Expression profile clustering and module identification using WGCNA. </plain></SENT>
<SENT sid="40" pm="."><plain>(5) Visualization of co-expression modules by Cytoscape. (B) Framework of module significance analyses. </plain></SENT>
<SENT sid="41" pm="."><plain>The details are provided in Methods. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec id="Sec2"><title><text><SENT sid="42" pm="."><plain>Methods </plain></SENT>
</text></title><sec id="Sec3"><title><text><SENT sid="43" pm="."><plain>Processing and analysis of microarray gene expression data </plain></SENT>
</text></title><p><text><SENT sid="44" pm="."><plain>Two microarray gene expression datasets were downloaded from the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/">http://www.ncbi.nlm.nih.gov/geo/</ext-link>). </plain></SENT>
<SENT sid="45" pm="."><plain>To ensure the data quality, we searched for studies that have a well-defined phenotypic description for PrCa, have a sample size around 100 or more, and have preferably been measured using similar platforms in order to obtain a high proportion of overlapping genes. </plain></SENT>
<SENT sid="46" pm="."><plain>We included both case and control samples to determine disease-specific signals, as similarly done in Chen et al. [21]. </plain></SENT>
<SENT sid="47" pm="."><plain>Two datasets that fulfilled these criteria were downloaded for our further analyses (Table 1). </plain></SENT>
<SENT sid="48" pm="."><plain>The first dataset (GEO accession ID: GSE17951 [33]), which was used as the training dataset in our work, was generated using the Affymetrix U133Plus2 array on prostate tissue samples from 109 cancer patients and 45 control samples [33] (Table 1). </plain></SENT>
<SENT sid="49" pm="."><plain>The second dataset (GEO accession ID: GSE6956 [10]), which was used as the testing dataset, was collected using the Affymetrix Human Genome U133A 2.0 array for 69 fresh-frozen prostate tumors and 20 control samples from surrounding normal prostate tissue [10]. </plain></SENT>
<SENT sid="50" pm="."><plain>For each dataset, we performed the following quality control steps. </plain></SENT>
<SENT sid="51" pm="."><plain>First, outlier samples were detected and removed. </plain></SENT>
<SENT sid="52" pm="."><plain>We calculated the inter-array correlation (IAC) based on Pearson’s correlation coefficient for tumor and control samples, respectively. </plain></SENT>
<SENT sid="53" pm="."><plain>We excluded the samples with low mean IAC and/or those that emerged as a clear outlier by the hierarchical clustering approach [34]. </plain></SENT>
<SENT sid="54" pm="."><plain>Second, samples were quantile-normalized after log2 transformation [35]. </plain></SENT>
<SENT sid="55" pm="."><plain>Probes with missing expression values in more than 30% samples were removed from further analyses. </plain></SENT>
<SENT sid="56" pm="."><plain>For each gene, we selected the probe with the highest intensity to represent the expression level of the gene. </plain></SENT>
<SENT sid="57" pm="."><plain>This resulted in 21,049 genes involved in 82 tumor and 40 control samples in the training dataset and 13,211 genes in 60 tumor and 19 normal samples in the testing dataset, with 13,211 genes shared by the two datasets.Table 1 Summarization of PrCa microarray gene expression datasets used in the study  aQC: quality control. </plain></SENT>
</text></p></sec><sec id="Sec4"><title><text><SENT sid="58" pm="."><plain>Highly-preserved GO_BP terms </plain></SENT>
</text></title><p><text><SENT sid="59" pm="."><plain>The GO database provides three annotation categories (domains): Molecular Function (MF), Biological Process (BP), and Cellular Component (CC). </plain></SENT>
<SENT sid="60" pm="."><plain>In this study, we focused on the BP category, based on the notion that genes that participate in the same biological processes tend to be expressed coordinately [36]. </plain></SENT>
<SENT sid="61" pm="."><plain>We downloaded the GO_BP gene sets from the Molecular Signatures Database (MSigDB) [37], including 825 GO_BP terms in the C5 category. </plain></SENT>
<SENT sid="62" pm="."><plain>To avoid too broadly or too narrowly defined GO_BP terms, we only kept the terms with 50 to 500 measured genes. </plain></SENT>
<SENT sid="63" pm="."><plain>As a result, 226 GO_BP terms were eligible to build the gene expression matrices for the following analysis. </plain></SENT>
</text></p><p><text><SENT sid="64" pm="."><plain>Before the construction of the modules, we first evaluated the importance of each term associated with PrCa by calculating a preservation score. </plain></SENT>
<SENT sid="65" pm="."><plain>The preservation score aims to assess the level of preservation between the training and testing datasets for a gene set (i.e., a GO_BP term) and is typically measured based on both density and connectivity patterns among the genes [29]. </plain></SENT>
<SENT sid="66" pm="."><plain>The parameter Zsummary[29] implemented in WGCNA [28] was employed to compute the preservation score. </plain></SENT>
<SENT sid="67" pm="."><plain>In general, a value of Zsummary &lt;2 indicates no evidence of preservation between the training and the testing datasets, 2 &lt; Zsummary &lt;10 implies weak to moderate evidence, and Zsummary &gt;10 indicates strong evidence. </plain></SENT>
<SENT sid="68" pm="."><plain>At this stage, we aim to perform pre-selection of GO_BP terms that are suitable for the following co-expression clustering analysis. </plain></SENT>
<SENT sid="69" pm="."><plain>To this end, we chose a moderate threshold of preservation, Zsummary = 5 [29], to select GO_BP terms and denote them as preserved GO_BP terms in both training and testing datasets. </plain></SENT>
</text></p></sec><sec id="Sec5"><title><text><SENT sid="70" pm="."><plain>Application of WGCNA in PrCa </plain></SENT>
</text></title><p><text><SENT sid="71" pm="."><plain>Given that genes within a GO_BP term are well-defined with similar biological functions, we asked whether they tend to co-express in a specific disease. </plain></SENT>
<SENT sid="72" pm="."><plain>Thus, we performed gene co-expression analysis for each preserved GO_BP term instead of all genes on the chip. </plain></SENT>
<SENT sid="73" pm="."><plain>We took the gene expression matrix for each GO_BP term as the input and applied WGCNA to detect co-expression modules. </plain></SENT>
<SENT sid="74" pm="."><plain>Gene co-expression correlation was measured by Pearson’s correlation coefficients. </plain></SENT>
<SENT sid="75" pm="."><plain>In this step, we built a pairwise co-expression matrix. </plain></SENT>
<SENT sid="76" pm="."><plain>This GO_BP term-based matrix was then utilized to construct an initial gene co-expression network by the blockwiseModules function in WGCNA. </plain></SENT>
<SENT sid="77" pm="."><plain>Notably, the initial co-expression network constructed and based only on Pearson’s correlation coefficients was not always a scale-free network. </plain></SENT>
<SENT sid="78" pm="."><plain>Rather, to obtain a scale-free network, a weighted adjacency matrix needs to be constructed using a selected power determined through a soft-thresholding approach in WGCNA. </plain></SENT>
</text></p><p><text><SENT sid="79" pm="."><plain>Co-expression modules were then defined by a robust dynamic hierarchical tree cut algorithm using the measurement of dissimilarity (i.e., 1-topological overlap matrix) [26, 38]. </plain></SENT>
<SENT sid="80" pm="."><plain>To ensure a suitable number of genes for next-step analysis, we set the minimum module size as 10. </plain></SENT>
<SENT sid="81" pm="."><plain>The adjacent modules were merged based on the parameter of cutHeight, i.e., modules with a minimum cutHeight at 0.25 were merged. </plain></SENT>
<SENT sid="82" pm="."><plain>Principle component analysis (PCA) of the expression matrix for each module was then performed. </plain></SENT>
<SENT sid="83" pm="."><plain>We denoted the first principal component (PC) as the module eigengene and used it to represent the overall expression profile of the module [39]. </plain></SENT>
<SENT sid="84" pm="."><plain>For each gene, we computed a module membership (kME) based on the correlation between the gene expression and the module eigengene. </plain></SENT>
<SENT sid="85" pm="."><plain>Those genes with a lower membership (kME ≤0.3) were removed from the module and assigned to the grey module. </plain></SENT>
</text></p><p><text><SENT sid="86" pm="."><plain>To validate whether the identified modules were associated with PrCa, we conducted a two-step evaluation procedure. </plain></SENT>
<SENT sid="87" pm="."><plain>First, for each module, we adopted the module eigengene to assess its trait association (denoted as pcor) based on Pearson’s correlation coefficients. </plain></SENT>
<SENT sid="88" pm="."><plain>We used the false positive rate (FDR) for multiple testing correction [40]. </plain></SENT>
<SENT sid="89" pm="."><plain>Second, for PrCa-associated modules, we further evaluated the module preservation in the testing dataset. </plain></SENT>
<SENT sid="90" pm="."><plain>Since the size of our identified module was generally less than 100, we defined a module to be preserved if it has a Zsummary (module) &gt;5. </plain></SENT>
</text></p></sec><sec id="Sec6"><title><text><SENT sid="91" pm="."><plain>Enrichment test </plain></SENT>
</text></title><p><text><SENT sid="92" pm="."><plain>Four types of large-scale, PrCa-associated genetic/genomic data, eQTL genes, recurrent SCNAs, somatic mutations, and prognostic genes were collected for the enrichment test of the identified modules. </plain></SENT>
<SENT sid="93" pm="."><plain>The eQTL genes were collected from the online eQTL database, SeeQTL (<ext-link ext-link-type="uri" xlink:href="http://www.bios.unc.edu/research/genomic_software/seeQTL/">http://www.bios.unc.edu/research/genomic_software/seeQTL/</ext-link>), which re-analyzed nine independent HapMap studies in lymphoblastoid cell lines (LCLs); performed a consensus meta-analysis with comprehensive quality control, population stratification control, and FDR control; and provided the q-value as the significance measurement [41–47]. </plain></SENT>
<SENT sid="94" pm="."><plain>We retrieved a total of 8652 genes regulated by cis-eQL (7071 genes) or trans-eQTL (4140 genes) from the SeeQTL database. </plain></SENT>
<SENT sid="95" pm="."><plain>Here, cis-eQTL represents the cases where the regulated genes are located within 1 Mb of the regulatory SNP, while trans-eQTL indicates associations for more distant eQTL. </plain></SENT>
<SENT sid="96" pm="."><plain>We denoted them as cis-eQTL and trans-eQTL gene sets, respectively. </plain></SENT>
</text></p><p><text><SENT sid="97" pm="."><plain>A list of PrCa susceptibility genes located in SCNA regions was downloaded from the cBio data portal [48]. </plain></SENT>
<SENT sid="98" pm="."><plain>These SCNA regions were obtained using GISTIC2 (q-value &lt;0.1) [49], based on The Cancer Genome Atlas (TCGA) prostate adenocarcinoma data (<ext-link ext-link-type="uri" xlink:href="https://tcga-data.nci.nih.gov/tcga/">https://tcga-data.nci.nih.gov/tcga/</ext-link>). </plain></SENT>
<SENT sid="99" pm="."><plain>In sum, we retrieved 567 unique genes and denoted them as the SCNA gene set. </plain></SENT>
</text></p><p><text><SENT sid="100" pm="."><plain>Genes with somatic mutations were collected from two sources. </plain></SENT>
<SENT sid="101" pm="."><plain>First, we manually collected 47 mutated genes from the Human Prostate Gene Database (PGDB) [17]. </plain></SENT>
<SENT sid="102" pm="."><plain>Second, 107 significantly mutated genes identified in the TCGA prostate adenocarcinoma (<ext-link ext-link-type="uri" xlink:href="https://tcga-data.nci.nih.gov/tcga/">https://tcga-data.nci.nih.gov/tcga/</ext-link>) samples were retrieved from the cBio portal. </plain></SENT>
<SENT sid="103" pm="."><plain>As a result, we obtained 149 unique genes and denoted them as the mutant gene set. </plain></SENT>
</text></p><p><text><SENT sid="104" pm="."><plain>We downloaded the RNASeqV2 and clinical data for prostate adenocarcinoma from the TCGA portal (<ext-link ext-link-type="uri" xlink:href="https://tcga-data.nci.nih.gov/tcga/">https://tcga-data.nci.nih.gov/tcga/</ext-link>). </plain></SENT>
<SENT sid="105" pm="."><plain>The Univariate Cox model was applied to define the prognostic genes [18]. </plain></SENT>
<SENT sid="106" pm="."><plain>FDR was applied for multiple testing correction of the raw Wald p values. </plain></SENT>
<SENT sid="107" pm="."><plain>Finally, we obtained 737 genes with FDR &lt; 0.05. </plain></SENT>
</text></p><p><text><SENT sid="108" pm="."><plain>Gene set enrichment analysis for PrCa-associated modules was performed using the hypergeometric test. </plain></SENT>
<SENT sid="109" pm="."><plain>Multiple testing correction was controlled by the FDR method. </plain></SENT>
<SENT sid="110" pm="."><plain>The module was taken as a candidate if it significantly enriched with any of the two gene sets among eQTL, SCNA, mutation, and prognostic genes with FDR &lt; 0.05. </plain></SENT>
<SENT sid="111" pm="."><plain>We further performed enrichment tests of the candidate module genes with TF and miRNA using the online tool WebGestalt [50]. </plain></SENT>
<SENT sid="112" pm="."><plain>The resultant p values were corrected for multiple testing using the FDR method. </plain></SENT>
<SENT sid="113" pm="."><plain>We set the significance level for FDR at 0.01 and the minimum number of genes for a category at two. </plain></SENT>
<SENT sid="114" pm="."><plain>For simplification, the top 5 enriched TFs or miRNAs were collected for further analyses. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec id="Sec7"><title><text><SENT sid="115" pm="."><plain>Results </plain></SENT>
</text></title><sec id="Sec8"><title><text><SENT sid="116" pm="."><plain>The identified GO_BP-based co-expression modules </plain></SENT>
</text></title><p><text><SENT sid="117" pm="."><plain>GO_BP terms categorize genes that function in the same or similar biological processes. </plain></SENT>
<SENT sid="118" pm="."><plain>Hence, genes in the same GO_BP term could be expected to have coordinated expression patterns. </plain></SENT>
<SENT sid="119" pm="."><plain>In our study, among the 226 GO_BP terms that fulfilled our query criteria (size between 50 and 500), 118 had a preservation score of Zsummary (GO_BP) &gt;5 and were considered well preserved between the training and the testing datasets. </plain></SENT>
<SENT sid="120" pm="."><plain>For each of these 118 GO_BP terms, we built a weighted co-expression network using the entire training dataset of 82 prostate tumor samples and 40 control samples (see Methods). </plain></SENT>
<SENT sid="121" pm="."><plain>Highly co-expressed genes within a term were then clustered into modules, each labeled with a specific color (Figure 1A4). </plain></SENT>
<SENT sid="122" pm="."><plain>This resulted in 548 modules in total. </plain></SENT>
<SENT sid="123" pm="."><plain>To examine their association with prostate cancer, we calculated the correlation between the module expression profiles (represented by the module eigengene) and the PrCa disease status (represented by a vector of 1 for case and 0 for control). </plain></SENT>
<SENT sid="124" pm="."><plain>With FDR &lt;0.05, we identified 294 of the 548 modules that showed statistically significant association with PrCa in the training dataset. </plain></SENT>
<SENT sid="125" pm="."><plain>To further evaluate the association, we calculated the preservation score, Zsummary, for each single module against the testing dataset. </plain></SENT>
<SENT sid="126" pm="."><plain>55 of the 294 modules were preserved with Zsummary (module) &gt;5. </plain></SENT>
<SENT sid="127" pm="."><plain>As shown in Additional file 1: Table S1, these 55 modules belong to 35 GO_BP terms. </plain></SENT>
<SENT sid="128" pm="."><plain>Many of these terms have been reported to be associated with cancer development, such as “biosynthetic process” [18], “cell-cell signaling” [51, 52], “inflammatory response” [53], “response to stress” [54], “post translational protein modification” [55], “immune system process” [56], “phosphorylation” [57], “regulation of apoptosis” [58], and “regulation of cell proliferation” [59] in many cancer types, including PrCa. </plain></SENT>
<SENT sid="129" pm="."><plain>Although expected, these results confirmed that the identified modules are important to PrCa, and the method for the analysis is reasonable. </plain></SENT>
<SENT sid="130" pm="."><plain>In addition, the successful detection indicates that there are indeed subsets of genes within each single GO_BP term that are co-expressed and associated with PrCa. </plain></SENT>
<SENT sid="131" pm="."><plain>This further verified the rationale of our procedure to examine co-expression patterns in each GO_BP term, rather than in the whole gene set on chip, and proved its ability to discover disease-associated genes and modules. </plain></SENT>
</text></p></sec><sec id="Sec9"><title><text><SENT sid="132" pm="."><plain>Characterization of the identified PrCa associated modules </plain></SENT>
</text></title><p><text><SENT sid="133" pm="."><plain>Our enrichment test of the 55 preserved PrCa-associated modules showed that six modules were significantly enriched with PrCa candidate genes, such as eQTL, SCNA, or mutant genes (FDR adjusted p &lt; 0.05) (Additional file 1: Table S1). </plain></SENT>
<SENT sid="134" pm="."><plain>Their functions are annotated as “response to stress (labeled in green in Figure 1A4)” (pcis-eQTL = 0.017, ptrans-eQTL = 3.16 × 10−3, pmutation = 1.37 × 10−3), “cellular localization (turquoise)” (pcis-eQTL = 7.30 × 10−3, pSCNA = 0.024, pprog =1.62 × 10−3), “protein localization (brown)” (pcis-eQTL = 0.034, pSCNA = 0.039, pmutation = 6.84 × 10−4), “regulation of apoptosis (green)” (pcis-eQTL = 8.93 × 10−3, pSCNA = 0.040), “regulation of apoptosis (red)” (pcis-eQTL = 0.027, ptrans-eQTL = 6.59 × 10−3, pmutation = 6.39 × 10−5), and “apoptosis go (black)” (pcis-eQTL = 8.93 × 10−3, ptrans-eQTL = 1.08 × 10−3, pmutation = 6.41 × 10−5). </plain></SENT>
<SENT sid="135" pm="."><plain>We calculated the pairwise similarities between the six modules using Fisher’s exact test. </plain></SENT>
<SENT sid="136" pm="."><plain>As a result, “regulation of apoptosis (red)” and “apoptosis go (black)” were found with a large proportion of overlapping genes (p = 3. </plain></SENT>
<SENT sid="137" pm="."><plain>7 × 10−41). </plain></SENT>
<SENT sid="138" pm="."><plain>We therefore merged these two modules and referred to the resultant module as M1. </plain></SENT>
<SENT sid="139" pm="."><plain>Other modules were listed as M2-M5, as summarized in Table 2.Table 2 Overview of enrichment analyses of the five identified PrCa modules  a p values were adjusted by FDR method. </plain></SENT>
</text></p><p><text><SENT sid="140" pm="."><plain>For these identified PrCa-associated modules, we recalculated the Module Membership (kME) of each gene by its correlation with the module eigengene (Additional file 2: Table S2). </plain></SENT>
<SENT sid="141" pm="."><plain>In particular, we presented the five modules in Figure 2, in which nodes were ranked by their kME values and edge thickness reflected the correlations’ coefficients. </plain></SENT>
<SENT sid="142" pm="."><plain>Node shapes represented different gene functions, as shown in Additional file 2: Table S2. </plain></SENT>
<SENT sid="143" pm="."><plain>Genes with higher kME values were highly interconnected in modules M1, M3, and M4, indicating a strong co-expression pattern in PrCa (Figure 2). </plain></SENT>
<SENT sid="144" pm="."><plain>In modules M2 and M5, relatively moderate connections were observed. </plain></SENT>
<SENT sid="145" pm="."><plain>This is likely due to a weak PrCa association (M2, pcor = 0.015) or a low preservation score (M5, Zsummary = 5.2). </plain></SENT>
<SENT sid="146" pm="."><plain>The biological functions of modules M1 and M2 are associated with the GO_BP term “apoptosis.” Representative genes include IL6[60], SOCS3[61], GADD45A[62], PIM1[63], 1L1B[64], CDKN1A[65], CCL2[66], PMAIP1 (also known as NOXA) [67], and RHOB[68] in module M1, and DHCR24[69], BNIP3[70], and IGF1R[71] in module M2. </plain></SENT>
<SENT sid="147" pm="."><plain>For modules M3, M4, and M5, although the corresponding GO_BP terms were not directly related to cancer, we found PrCa-relevant genes in these three modules, including BTG2[72], FOS (also known as c-Fos) [73], and CXCR4[74] in module M3; ARFGAP3[75] and CDH1[76] in module M4; and SMAD3[77] and MXI1[78] in module M5.Figure 2 Visualization of the five identified PrCa-associated modules. To better describe the modules, we ranked nodes by their module membership (kME) values, and the edge widths are proportional to their correlations. </plain></SENT>
<SENT sid="148" pm="."><plain>Legends are listed at the bottom for clarity. </plain></SENT>
</text></p><p><text><SENT sid="149" pm="."><plain>Moreover, we identified TF and microRNA regulators enriched in the modules, and the results are shown in Table 3. </plain></SENT>
<SENT sid="150" pm="."><plain>Some TFs could be seen as associated with several modules. </plain></SENT>
<SENT sid="151" pm="."><plain>For example, modules M1 and M3 were significantly enriched with the nuclear factor of activated T-cell transcription factor gene, NFAT (pM1 = 3.59 × 10−7, pM3 = 2.20 × 10−5). </plain></SENT>
<SENT sid="152" pm="."><plain>All the other three modules—M2, M4, and M5—were significantly enriched with the gene specificity protein 1, SP1 (pM2 = 3.00 × 10−4, pM4 = 4.00 × 10−4, pM5 = 1.20 × 10−3) (Figure 2). </plain></SENT>
<SENT sid="153" pm="."><plain>Both NFAT and SP1 were known to be associated with PrCa [79, 80].Table 3 Transcription factors (TFs) and microRNAs (miRNAs) identified by the analyses of PrCa-associated modules (M1-M5) TFs and miRNAs in italics were those shared between modules and associated with prostate cancer. a p values were adjusted by FDR method. </plain></SENT>
</text></p><p><text><SENT sid="154" pm="."><plain>To further search for evidence of the coordinated regulation of each identified module, we explored the module eigengene in tumor and control samples for all five modules. </plain></SENT>
<SENT sid="155" pm="."><plain>As shown in Figure 3, the eigengenes of modules M1, M2, M3, and M4 were consistently over-expressed in PrCa tumor samples compared to control samples, while the eigengene of module M5 was under-expressed. </plain></SENT>
<SENT sid="156" pm="."><plain>These observations implied that the module genes might be co-regulated by the same or similar regulators, e.g., TFs (or their regulators) or miRNAs that regulate the expression of the module genes. </plain></SENT>
<SENT sid="157" pm="."><plain>We therefore examined the correlation between the candidate TFs (Table 3) with PrCa. </plain></SENT>
<SENT sid="158" pm="."><plain>Specifically, the TF NFAT family genes, such as NFATC4 (pcor1 = 8.94 × 10−7, pcor2 = 7.66 × 10−4) and NFATC1 (pcor1 = 2.25 × 10−3, pcor2 = 3.61 × 10−2), were associated with PrCa. </plain></SENT>
<SENT sid="159" pm="."><plain>The activation of partner gene TRPV6 was reported to be critical to NFAT [79, 81] in prostate cancer cells. </plain></SENT>
<SENT sid="160" pm="."><plain>Our specific examination showed that TRPV6 was significantly over-expressed in PrCa tumor samples (pcor1 = 6.49 × 10−6) in the training dataset, but not in the testing dataset (pcor2 = 0.12). </plain></SENT>
<SENT sid="161" pm="."><plain>In addition, other enriched TFs showed promising evidence (Table 3) for association with PrCa, such as SP1 (pcor1 = 4.60 × 10−7 and pcor2 = 7.50 × 10−5), REL (pcor1 = 8.08 × 10-10,pcor2 = 0.010), and JUN (pcor1 = 5.91 × 10-15,pcor2 = 7.70 × 10−5) in module M1; RFX1 (pcor1 = 3.67 × 10-5,pcor2 = 3.10 × 10−6), VSX1 (pcor1 = 1.55 × 10-4,pcor2 = 0.036), and RORA (pcor1 = 1.29 × 10-3,pcor2 = 3.15 × 10−11) in module M2; NF1 (pcor1 = 1.14 × 10-3,pcor2 = 6.01 × 10−5) in module M4; and CDC5L (pcor1 = 0.012,pcor2 = 8.07 × 10−6) in module M5.Figure 3 Expression of module eigengenes in five modules (M1-M5) across samples. Blue indicates tumor samples, while red indicates control samples. </plain></SENT>
</text></p><p><text><SENT sid="162" pm="."><plain>In Table 3, we listed the enriched miRNAs; several of them have been reported to be associated with PrCa, such as hsa-miR-19a [82] with modules M1 and M3 (pM1 = 3.50 × 10−3, pM3 = 6.10 × 10−3), hsa-miR-15a [83] with modules M4 and M5 (pM4 = 4.70 × 10−3, pM5 = 3.00 × 10−4), and hsa-miR-200b [84] with module M2 (pM2 = 9.00 × 10−3). </plain></SENT>
<SENT sid="163" pm="."><plain>For the other microRNAs, experimental validation is needed to investigate their roles in PrCa. </plain></SENT>
</text></p><p><text><SENT sid="164" pm="."><plain>In order to validate the regulatory TFs/miRNAs detected above, we retrieved RNASeqV2 and miRNASeq data for prostate adenocarcinoma from the TCGA portal to build the expression matrix. </plain></SENT>
<SENT sid="165" pm="."><plain>The R package edgeR [85] was applied to obtain the differentially expressed genes and miRNAs. </plain></SENT>
<SENT sid="166" pm="."><plain>The FDR method was applied to adjust p values for multiple testing. </plain></SENT>
<SENT sid="167" pm="."><plain>We found that the identified key TF regulators, including NFAT family genes (pNFATC4 = 7.85 × 10−12, pNFAT5 = 6.76 × 10−6, pNFATC2 = 6.79 × 10−6, pNFATC3 = 6.95 × 10−3), NFAT regulator TRPV6 (p = 1.40 × 10−6), and SP1 (p = 9.49 × 10−3), were highly differentially expressed, as well as the other enriched TFs, such as REL (p = 1.35 × 10−5), RORA (p = 1.54 × 10−13), and NF1 (p = 6.24 × 10−4). </plain></SENT>
<SENT sid="168" pm="."><plain>Similar patterns were also observed in the identified miRNAs, such as hsa-miR-19a (p = 1.72 × 10−12), hsa-miR-15a (p = 8.10 × 10−10), and hsa-miR-200b (p = 6.39 × 10−3). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="Sec10"><title><text><SENT sid="169" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="170" pm="."><plain>High-throughput genetic and genomic studies have demonstrated that GO terms are important prior knowledge in facilitating and interpreting of discoveries in complex disease studies. </plain></SENT>
<SENT sid="171" pm="."><plain>In this study, we identified gene co-expression modules within GO_BP terms for PrCa. </plain></SENT>
<SENT sid="172" pm="."><plain>We found 118 GO_BP terms that were preserved between training and testing datasets, some of them have been widely studied and reported, such as “programmed cell death” [86], “cell-cell adhesion” [87], and “regulation of apoptosis” [87]. </plain></SENT>
<SENT sid="173" pm="."><plain>We applied WGCNA to the PrCa expression data sets and identified five co-expression modules which were preserved in the training and testing datasets and enriched with known PrCa genes. </plain></SENT>
<SENT sid="174" pm="."><plain>In our further evaluation of these modules, we identified several PrCa associated TFs and miRNAs as putative key regulators in PrCa genesis and progression. </plain></SENT>
</text></p><p><text><SENT sid="175" pm="."><plain>To evaluate the performance of our approach, we applied another popular co-expression network reconstruction algorithm, K-means [88], to the GO_BP-based expression matrices. </plain></SENT>
<SENT sid="176" pm="."><plain>For each GO_BP term, the number of modules obtained from WGCNA was assigned to K-means. </plain></SENT>
<SENT sid="177" pm="."><plain>Among the 548 constructed modules, only 12 modules showed significant association with PrCa status (FDR &lt; 0.05) and were preserved in the testing dataset (Zsummary &gt; 5). </plain></SENT>
<SENT sid="178" pm="."><plain>Further enrichment tests showed that these 12 modules were poorly enriched in the collected PrCa genes (Additional file 3: Table S3). </plain></SENT>
<SENT sid="179" pm="."><plain>Since the module preservation calculation is computationally time-consuming, we did not perform other algorithms for comparison. </plain></SENT>
<SENT sid="180" pm="."><plain>Although more comparison with other methods may be needed, the WGCNA approach seems to be effective on detecting the risk modules for PrCa. </plain></SENT>
</text></p><p><text><SENT sid="181" pm="."><plain>The results revealed that the co-expression modules that belong to known cancer-related GO terms could play regulatory roles in PrCa, such as the two apoptosis-related candidate modules, M1 and M2. </plain></SENT>
<SENT sid="182" pm="."><plain>The results also indicated that those modules associated with general terms, e.g., “response to stress,” “cellular localization,” and “protein localization,” may contribute to PrCa risk in a synergistic way. </plain></SENT>
<SENT sid="183" pm="."><plain>As a core signaling pathway in cancers [89–92], apoptosis-blocking has proven to be very important in cell development [58, 93] during the stages of progression from normal epithelial cells, to androgen-dependent tumor cells, and further to malignant androgen-independent ones. </plain></SENT>
<SENT sid="184" pm="."><plain>On the other hand, cells can be activated in various ways in response to stress during cell development, mainly to maintain the balance between cell death and cell proliferation [94]. </plain></SENT>
<SENT sid="185" pm="."><plain>Therefore, cells that experience too much stress, e.g., an over-expressed module M3, may bring down the rate of cancer cell death and thus result in the formation of cancer [95–97]. </plain></SENT>
<SENT sid="186" pm="."><plain>As indicated by previous studies [98, 99], we then considered that the alternation of expression for genes involved in cellular and protein localizations play critical roles during cell-division and cancer cell proliferation, such as through modules M4 and M5; studying the localizations of these genes and their encoded proteins can help us elucidate the molecular basis of cancer genesis and progression [100, 101]. </plain></SENT>
</text></p><p><text><SENT sid="187" pm="."><plain>As we found, different modules may share the same genetic regulator, such as TF and miRNA. </plain></SENT>
<SENT sid="188" pm="."><plain>An intriguing example is the TF, NFAT, enriched by both modules M1 and M3. </plain></SENT>
<SENT sid="189" pm="."><plain>NFAT is reported to promote the epithelial cell proliferation of human primary PrCa [79, 81] with store-independent Ca2+ entry via the TRPV6 channel. </plain></SENT>
<SENT sid="190" pm="."><plain>Significant expression changes of NFAT family genes and their regulator TRPV6 were observed in PrCa in the datasets. </plain></SENT>
<SENT sid="191" pm="."><plain>Another TF, SP1, was found to be PrCa-associated and enriched in three modules: M2, M4, and M5. </plain></SENT>
<SENT sid="192" pm="."><plain>SP1 has been considered an important target for PrCa therapy, since it regulates important genes, like the androgen receptor gene (AR), TGF-β, c-Met and prostate specific antigen (PSA), and others. </plain></SENT>
<SENT sid="193" pm="."><plain>These genes are involved in cell cycle, proliferation, cell differentiation, and apoptosis [80]. </plain></SENT>
<SENT sid="194" pm="."><plain>Other enriched TFs, STAT1 and NFKB [102], and moderately enriched miRNAs, hsa-miR-15a [83] and hsa-miR-19a [82] (Table 3), are also reported to be associated with PrCa. </plain></SENT>
<SENT sid="195" pm="."><plain>Similar expression patterns were also observed in another independent TCGA dataset. </plain></SENT>
<SENT sid="196" pm="."><plain>Taken together, our findings suggested that these 5 modules and their TF and microRNA regulators are likely critical for the genesis and progression of PrCa. </plain></SENT>
<SENT sid="197" pm="."><plain>These modules and regulators may be molecular targets for the future development of drugs and new therapies. </plain></SENT>
</text></p><p><text><SENT sid="198" pm="."><plain>In this study, we chose a relatively stringent significance level to detect candidate modules. </plain></SENT>
<SENT sid="199" pm="."><plain>The identified modules need to be enriched with both eQTL genes and SCNA or mutated genes, with a corrected p &lt;0.05. </plain></SENT>
<SENT sid="200" pm="."><plain>This might exclude moderately associated modules (e.g., p &lt;0.2), such as “response to chemical stimulus (in turquoise in Figure 1A4) (ptrans-eQTL = 0.086, pSCNA = 0.062),” “regulation of apoptosis (turquoise) (pcis-eQTL = 0.075, pSCNA = 0.039),” and “apoptosis go (turquoise) (pcis-eQTL = 0.071, pSCNA = 0.024)” (Additional file 1: Table S1). </plain></SENT>
</text></p><p><text><SENT sid="201" pm="."><plain>In summary, our findings indicate that genes with same GO functions can cluster into several co-expressed modules to contribute to PrCa, as seen in modules M1 and M2. </plain></SENT>
<SENT sid="202" pm="."><plain>Modules across GO terms may act in the networks that are regulated by same genetic factors, such as modules M1 and M3. </plain></SENT>
<SENT sid="203" pm="."><plain>These findings indicate the importance of studying PrCa development at a systems level rather than at a single-gene level, offering insights into the underlying mechanisms of PrCa. </plain></SENT>
</text></p></sec></SecTag><SecTag type="CONCL"><sec id="Sec11"><title><text><SENT sid="204" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><text><SENT sid="205" pm="."><plain>Using GO_BP terms to start, we conducted gene co-expression analysis of expression profiles of PrCa. </plain></SENT>
<SENT sid="206" pm="."><plain>Our results revealed five modules that were differentially expressed between tumors and controls, preserved between independent expression datasets, and enriched with putative cancer genes. </plain></SENT>
<SENT sid="207" pm="."><plain>The enrichment analyses further identified TF and miRNA as key regulators in PrCa. </plain></SENT>
<SENT sid="208" pm="."><plain>Our study provides important insights for the future investigation of molecular functionality related to PrCa etiology and the development of PrCa diagnosis tools and targeted therapy strategies. </plain></SENT>
</text></p></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material"><title><text><SENT sid="209" pm="."><plain>Electronic supplementary material </plain></SENT>
</text></title><sec id="Sec12"><supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12864_2014_6720_MOESM1_ESM.docx"><caption><p><text><SENT sid="210" pm="."><plain>Additional file 1: Table S1.: Enrichment analyses of 55 preserved prostate cancer associated modules and preservation summary of corresponding GO_BP terms. </plain></SENT>
<SENT sid="211" pm="."><plain>(DOCX 47 KB) </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12864_2014_6720_MOESM2_ESM.docx"><caption><p><text><SENT sid="212" pm="."><plain>Additional file 2: Table S2.: Summarization of modules M1 ~ M5. </plain></SENT>
<SENT sid="213" pm="."><plain>(DOCX 260 KB) </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="12864_2014_6720_MOESM3_ESM.docx"><caption><p><text><SENT sid="214" pm="."><plain>Additional file 3: Table S3.: Enrichment analyses of 12 preserved prostate cancer-associated modules by K-means algorithm. </plain></SENT>
<SENT sid="215" pm="."><plain>(DOCX 27 KB) </plain></SENT>
</text></p></caption></media></supplementary-material></sec></sec></SecTag></body><back><fn-group><fn><p><text><SENT sid="216" pm="."><plain>Competing interest </plain></SENT>
</text></p><p><text><SENT sid="217" pm="."><plain>The authors declare that they have no competing interests. </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="218" pm="."><plain>Authors’ contributions </plain></SENT>
</text></p><p><text><SENT sid="219" pm="."><plain>BS, ZZ, and PJ conceived and designed the experiments. </plain></SENT>
<SENT sid="220" pm="."><plain>JJ and PJ performed the experiments. </plain></SENT>
<SENT sid="221" pm="."><plain>JJ and PJ analyzed the data. </plain></SENT>
<SENT sid="222" pm="."><plain>JJ, PJ, ZZ, and BS wrote the paper. </plain></SENT>
<SENT sid="223" pm="."><plain>All authors read and approved the final manuscript. </plain></SENT>
</text></p></fn></fn-group><SecTag type="ACK_FUND"><ack><title>Acknowledgements</title><p><text4fund><text><SENT sid="224" pm="."><plain>This work was partially supported by National Institutes of Health grants (R01LM011177, P50CA095103, P50CA098131, and P30CA068485) and Ingram Professorship Funds (to ZZ). </plain></SENT>
<SENT sid="225" pm="."><plain>We gratefully acknowledge financial support from National Natural Science Foundation of China grants (31470821, 91230117, and 31170795) and the program of China Scholarship Council (No. 201206920018). </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list id="Bib1"><title>References</title><ref id="CR1"><text><SENT sid="226" pm="."><plain>1.BaadePDYouldenDRKrnjackiLJInternational epidemiology of prostate cancer: geographical distribution and secular trendsMol Nutr Food Res200953217118410.1002/mnfr.200700511<?supplied-pmid 19101947?>19101947 </plain></SENT>
</text></ref><ref id="CR2"><text><SENT sid="227" pm="."><plain>2.SiegelRWardEBrawleyOJemalACancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deathsCA Cancer J Clin201161421223610.3322/caac.20121<?supplied-pmid 21685461?>21685461 </plain></SENT>
</text></ref><ref id="CR3"><text><SENT sid="228" pm="."><plain>3.GannPHRisk factors for prostate cancerRev Urol20024Suppl 5S3S10<?supplied-pmid 16986064?>16986064 </plain></SENT>
</text></ref><ref id="CR4"><text><SENT sid="229" pm="."><plain>4.NelsonWGDe MarzoAMIsaacsWBProstate cancerN Engl J Med2003349436638110.1056/NEJMra021562<?supplied-pmid 12878745?>12878745 </plain></SENT>
</text></ref><ref id="CR5"><text><SENT sid="230" pm="."><plain>5.ChenJZhangDYanWYangDShenBTranslational bioinformatics for diagnostic and prognostic prediction of prostate cancer in the next-generation sequencing EraBiomed Res Int201320136589252 </plain></SENT>
</text></ref><ref id="CR6"><text><SENT sid="231" pm="."><plain>6.LichtensteinPHolmNVVerkasaloPKIliadouAKaprioJKoskenvuoMPukkalaESkyttheAHemminkiKEnvironmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and FinlandN Engl J Med20003432788510.1056/NEJM200007133430201<?supplied-pmid 10891514?>10891514 </plain></SENT>
</text></ref><ref id="CR7"><text><SENT sid="232" pm="."><plain>7.PageWFBraunMMPartinAWCaporasoNWalshPHeredity and prostate cancer: a study of World War II veteran twinsProstate199733424024510.1002/(SICI)1097-0045(19971201)33:4&lt;240::AID-PROS3&gt;3.0.CO;2-L<?supplied-pmid 9397195?>9397195 </plain></SENT>
</text></ref><ref id="CR8"><text><SENT sid="233" pm="."><plain>8.JiaZWangYSawyersAYaoHRahmatpanahFXiaXQXuQPioRTuranTKoziolJAGoodisonSCarpenterPWang-RodriguezJSimoneauAMeyskensFSuttonMLernhardtWBeachTMonforteJMcClellandMMercolaDDiagnosis of prostate cancer using differentially expressed genes in stromaCancer Res20117172476248710.1158/0008-5472.CAN-10-2585<?supplied-pmid 21459804?>21459804 </plain></SENT>
</text></ref><ref id="CR9"><text><SENT sid="234" pm="."><plain>9.LiYVongsangnakWChenLShenBIntegrative analysis reveals disease-associated genes and biomarkers for prostate cancer progressionBMC Med Genet20147Suppl 1S3 </plain></SENT>
</text></ref><ref id="CR10"><text><SENT sid="235" pm="."><plain>10.WallaceTAPrueittRLYiMHoweTMGillespieJWYfantisHGStephensRMCaporasoNELoffredoCAAmbsSTumor immunobiological differences in prostate cancer between African-American and European-American menCancer Res200868392793610.1158/0008-5472.CAN-07-2608<?supplied-pmid 18245496?>18245496 </plain></SENT>
</text></ref><ref id="CR11"><text><SENT sid="236" pm="."><plain>11.WangYChenJLiQWangHLiuGJingQShenBIdentifying novel prostate cancer associated pathways based on integrative microarray data analysisComput Biol Chem201135315115810.1016/j.compbiolchem.2011.04.003<?supplied-pmid 21704261?>21704261 </plain></SENT>
</text></ref><ref id="CR12"><text><SENT sid="237" pm="."><plain>12.ChenJWangYShenBZhangDMolecular signature of cancer at gene level or pathway level? case studies of colorectal cancer and prostate cancer microarray dataComput Math Methods Med20132013909525<?supplied-pmid 23401724?>23401724 </plain></SENT>
</text></ref><ref id="CR13"><text><SENT sid="238" pm="."><plain>13.GrisanzioCWernerLTakedaDAwoyemiBCPomerantzMMYamadaHSooriakumaranPRobinsonBDLeungRSchinzelACMillsIRoss-AdamsHNealDEKidoMYamamotoTPetrozzielloGStackECLisRKantoffPWLodaMSartorOEgawaSTewariAKHahnWCFreedmanMLGenetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesisProc Natl Acad Sci U S A201210928112521125710.1073/pnas.1200853109<?supplied-pmid 22730461?>22730461 </plain></SENT>
</text></ref><ref id="CR14"><text><SENT sid="239" pm="."><plain>14.ZhangWZangJJingXSunZYanWYangDGuoFShenBIdentification of candidate miRNA biomarkers from miRNA regulatory network with application to prostate cancerJ Transl Med2014126610.1186/1479-5876-12-66<?supplied-pmid 24618011?>24618011 </plain></SENT>
</text></ref><ref id="CR15"><text><SENT sid="240" pm="."><plain>15.JiangJJiaPShenBZhaoZTop associated SNPs in prostate cancer are significantly enriched in cis-expression quantitative trait loci and at transcription factor binding sitesOncotarget20145156168617710.18632/oncotarget.2179<?supplied-pmid 25026280?>25026280 </plain></SENT>
</text></ref><ref id="CR16"><text><SENT sid="241" pm="."><plain>16.LiuWSunJLiGZhuYZhangSKimSTWiklundFWileyKIsaacsSDStattinPXuJDugganDCarptenJDIsaacsWBGronbergHZhengSLChangBLAssociation of a germ-line copy number variation at 2p24.3 and risk for aggressive prostate cancerCancer Res20096962176217910.1158/0008-5472.CAN-08-3151<?supplied-pmid 19258504?>19258504 </plain></SENT>
</text></ref><ref id="CR17"><text><SENT sid="242" pm="."><plain>17.LiLCZhaoHShiinaHKaneCJDahiyaRPGDB: a curated and integrated database of genes related to the prostateNucleic Acids Res200331129129310.1093/nar/gkg008<?supplied-pmid 12520005?>12520005 </plain></SENT>
</text></ref><ref id="CR18"><text><SENT sid="243" pm="."><plain>18.YangYHanLYuanYLiJHeiNLiangHGene co-expression network analysis reveals common system-level properties of prognostic genes across cancer typesNat Commun201453231<?supplied-pmid 24488081?>24488081 </plain></SENT>
</text></ref><ref id="CR19"><text><SENT sid="244" pm="."><plain>19.TangYYanWChenJLuoCKaipiaAShenBIdentification of novel microRNA regulatory pathways associated with heterogeneous prostate cancerBMC Syst Biol20137Suppl 3S610.1186/1752-0509-7-S3-S6<?supplied-pmid 24555436?>24555436 </plain></SENT>
</text></ref><ref id="CR20"><text><SENT sid="245" pm="."><plain>20.FeldmanBJFeldmanDThe development of androgen-independent prostate cancerNat Rev Cancer200111344510.1038/35094009<?supplied-pmid 11900250?>11900250 </plain></SENT>
</text></ref><ref id="CR21"><text><SENT sid="246" pm="."><plain>21.ChenCChengLGrennanKPibiriFZhangCBadnerJAGershonESLiuCTwo gene co-expression modules differentiate psychotics and controlsMol Psychiatry201218121308131410.1038/mp.2012.146<?supplied-pmid 23147385?>23147385 </plain></SENT>
</text></ref><ref id="CR22"><text><SENT sid="247" pm="."><plain>22.StamatoyannopoulosJAThe genomics of gene expressionGenomics200484344945710.1016/j.ygeno.2004.05.002<?supplied-pmid 15498452?>15498452 </plain></SENT>
</text></ref><ref id="CR23"><text><SENT sid="248" pm="."><plain>23.BarabasiALGulbahceNLoscalzoJNetwork medicine: a network-based approach to human diseaseNat Rev Genet2011121566810.1038/nrg2918<?supplied-pmid 21164525?>21164525 </plain></SENT>
</text></ref><ref id="CR24"><text><SENT sid="249" pm="."><plain>24.RhodesDRBarretteTRRubinMAGhoshDChinnaiyanAMMeta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancerCancer Res2002621544274433<?supplied-pmid 12154050?>12154050 </plain></SENT>
</text></ref><ref id="CR25"><text><SENT sid="250" pm="."><plain>25.StuartJMSegalEKollerDKimSKA gene-coexpression network for global discovery of conserved genetic modulesScience2003302564324925510.1126/science.1087447<?supplied-pmid 12934013?>12934013 </plain></SENT>
</text></ref><ref id="CR26"><text><SENT sid="251" pm="."><plain>26.ZhangBHorvathSA general framework for weighted gene co-expression network analysisStat Appl Genet Mol Biol20054Article17<?supplied-pmid 16646834?>16646834 </plain></SENT>
</text></ref><ref id="CR27"><text><SENT sid="252" pm="."><plain>27.Ben-DavidEShifmanSNetworks of neuronal genes affected by common and rare variants in autism spectrum disordersPLoS Genet201283e100255610.1371/journal.pgen.1002556<?supplied-pmid 22412387?>22412387 </plain></SENT>
</text></ref><ref id="CR28"><text><SENT sid="253" pm="."><plain>28.LangfelderPHorvathSWGCNA: an R package for weighted correlation network analysisBMC Bioinformatics2008955910.1186/1471-2105-9-559<?supplied-pmid 19114008?>19114008 </plain></SENT>
</text></ref><ref id="CR29"><text><SENT sid="254" pm="."><plain>29.LangfelderPLuoROldhamMCHorvathSIs my network module preserved and reproducible?PLoS Comput Biol201171e100105710.1371/journal.pcbi.1001057<?supplied-pmid 21283776?>21283776 </plain></SENT>
</text></ref><ref id="CR30"><text><SENT sid="255" pm="."><plain>30.OldhamMCKonopkaGIwamotoKLangfelderPKatoTHorvathSGeschwindDHFunctional organization of the transcriptome in human brainNat Neurosci200811111271128210.1038/nn.2207<?supplied-pmid 18849986?>18849986 </plain></SENT>
</text></ref><ref id="CR31"><text><SENT sid="256" pm="."><plain>31.MillerJAHorvathSGeschwindDHDivergence of human and mouse brain transcriptome highlights Alzheimer disease pathwaysProc Natl Acad Sci U S A201010728126981270310.1073/pnas.0914257107<?supplied-pmid 20616000?>20616000 </plain></SENT>
</text></ref><ref id="CR32"><text><SENT sid="257" pm="."><plain>32.AshburnerMBallCABlakeJABotsteinDButlerHCherryJMDavisAPDolinskiKDwightSSEppigJTHarrisMAHillDPIssel-TarverLKasarskisALewisSMateseJCRichardsonJERingwaldMRubinGMSherlockGGene ontology: tool for the unification of biology. </plain></SENT>
<SENT sid="258" pm="."><plain>The gene ontology consortiumNat Genet2000251252910.1038/75556<?supplied-pmid 10802651?>10802651 </plain></SENT>
</text></ref><ref id="CR33"><text><SENT sid="259" pm="."><plain>33.WangYXiaXQJiaZSawyersAYaoHWang-RodriquezJMercolaDMcClellandMIn silico estimates of tissue components in surgical samples based on expression profiling dataCancer Res201070166448645510.1158/0008-5472.CAN-10-0021<?supplied-pmid 20663908?>20663908 </plain></SENT>
</text></ref><ref id="CR34"><text><SENT sid="260" pm="."><plain>34.VoineaguIWangXJohnstonPLoweJKTianYHorvathSMillJCantorRMBlencoweBJGeschwindDHTranscriptomic analysis of autistic brain reveals convergent molecular pathologyNature2011474735138038410.1038/nature10110<?supplied-pmid 21614001?>21614001 </plain></SENT>
</text></ref><ref id="CR35"><text><SENT sid="261" pm="."><plain>35.IrizarryRABolstadBMCollinFCopeLMHobbsBSpeedTPSummaries of Affymetrix GeneChip probe level dataNucleic Acids Res2003314e1510.1093/nar/gng015<?supplied-pmid 12582260?>12582260 </plain></SENT>
</text></ref><ref id="CR36"><text><SENT sid="262" pm="."><plain>36.BrownMPGrundyWNLinDCristianiniNSugnetCWFureyTSAresMJrHausslerDKnowledge-based analysis of microarray gene expression data by using support vector machinesProc Natl Acad Sci U S A200097126226710.1073/pnas.97.1.262<?supplied-pmid 10618406?>10618406 </plain></SENT>
</text></ref><ref id="CR37"><text><SENT sid="263" pm="."><plain>37.SubramanianATamayoPMoothaVKMukherjeeSEbertBLGilletteMAPaulovichAPomeroySLGolubTRLanderESMesirovJPGene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profilesProc Natl Acad Sci U S A200510243155451555010.1073/pnas.0506580102<?supplied-pmid 16199517?>16199517 </plain></SENT>
</text></ref><ref id="CR38"><text><SENT sid="264" pm="."><plain>38.LangfelderPZhangBHorvathSDefining clusters from a hierarchical cluster tree: the Dynamic Tree Cut package for RBioinformatics200824571972010.1093/bioinformatics/btm563<?supplied-pmid 18024473?>18024473 </plain></SENT>
</text></ref><ref id="CR39"><text><SENT sid="265" pm="."><plain>39.LangfelderPHorvathSEigengene networks for studying the relationships between co-expression modulesBMC Syst Biol200715410.1186/1752-0509-1-54<?supplied-pmid 18031580?>18031580 </plain></SENT>
</text></ref><ref id="CR40"><text><SENT sid="266" pm="."><plain>40.StoreyJDTibshiraniRStatistical significance for genomewide studiesProc Natl Acad Sci U S A2003100169440944510.1073/pnas.1530509100<?supplied-pmid 12883005?>12883005 </plain></SENT>
</text></ref><ref id="CR41"><text><SENT sid="267" pm="."><plain>41.SpielmanRSBastoneLABurdickJTMorleyMEwensWJCheungVGCommon genetic variants account for differences in gene expression among ethnic groupsNat Genet200739222623110.1038/ng1955<?supplied-pmid 17206142?>17206142 </plain></SENT>
</text></ref><ref id="CR42"><text><SENT sid="268" pm="."><plain>42.StrangerBEForrestMSDunningMIngleCEBeazleyCThorneNRedonRBirdCPde GrassiALeeCTyler-SmithCCarterNSchererSWTavareSDeloukasPHurlesMEDermitzakisETRelative impact of nucleotide and copy number variation on gene expression phenotypesScience2007315581384885310.1126/science.1136678<?supplied-pmid 17289997?>17289997 </plain></SENT>
</text></ref><ref id="CR43"><text><SENT sid="269" pm="."><plain>43.ChoyEYelenskyRBonakdarSPlengeRMSaxenaRDe JagerPLShawSYWolfishCSSlavikJMCotsapasCRivasMDermitzakisETCahir-McFarlandEKieffEHaflerDDalyMJAltshulerDGenetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell linesPLoS Genet2008411e100028710.1371/journal.pgen.1000287<?supplied-pmid 19043577?>19043577 </plain></SENT>
</text></ref><ref id="CR44"><text><SENT sid="270" pm="."><plain>44.PriceALPattersonNHancksDCMyersSReichDCheungVGSpielmanRSEffects of cis and trans genetic ancestry on gene expression in African AmericansPLoS Genet2008412e100029410.1371/journal.pgen.1000294<?supplied-pmid 19057673?>19057673 </plain></SENT>
</text></ref><ref id="CR45"><text><SENT sid="271" pm="."><plain>45.DimasASDeutschSStrangerBEMontgomerySBBorelCAttar-CohenHIngleCBeazleyCGutierrez ArcelusMSekowskaMGagnebinMNisbettJDeloukasPDermitzakisETAntonarakisSECommon regulatory variation impacts gene expression in a cell type-dependent mannerScience200932559451246125010.1126/science.1174148<?supplied-pmid 19644074?>19644074 </plain></SENT>
</text></ref><ref id="CR46"><text><SENT sid="272" pm="."><plain>46.MontgomerySBSammethMGutierrez-ArcelusMLachRPIngleCNisbettJGuigoRDermitzakisETTranscriptome genetics using second generation sequencing in a Caucasian populationNature2010464728977377710.1038/nature08903<?supplied-pmid 20220756?>20220756 </plain></SENT>
</text></ref><ref id="CR47"><text><SENT sid="273" pm="."><plain>47.PickrellJKMarioniJCPaiAADegnerJFEngelhardtBENkadoriEVeyrierasJBStephensMGiladYPritchardJKUnderstanding mechanisms underlying human gene expression variation with RNA sequencingNature2010464728976877210.1038/nature08872<?supplied-pmid 20220758?>20220758 </plain></SENT>
</text></ref><ref id="CR48"><text><SENT sid="274" pm="."><plain>48.CeramiEGaoJDogrusozUGrossBESumerSOAksoyBAJacobsenAByrneCJHeuerMLLarssonEAntipinYRevaBGoldbergAPSanderCSchultzNThe cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics dataCancer Discov20122540140410.1158/2159-8290.CD-12-0095<?supplied-pmid 22588877?>22588877 </plain></SENT>
</text></ref><ref id="CR49"><text><SENT sid="275" pm="."><plain>49.MermelCHSchumacherSEHillBMeyersonMLBeroukhimRGetzGGISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancersGenome Biol2011124R4110.1186/gb-2011-12-4-r41<?supplied-pmid 21527027?>21527027 </plain></SENT>
</text></ref><ref id="CR50"><text><SENT sid="276" pm="."><plain>50.ZhangBKirovSSnoddyJWebGestalt: an integrated system for exploring gene sets in various biological contextsNucleic Acids Res200533Web Server issueW741W74810.1093/nar/gki475<?supplied-pmid 15980575?>15980575 </plain></SENT>
</text></ref><ref id="CR51"><text><SENT sid="277" pm="."><plain>51.IakouchevaLMBrownCJLawsonJDObradovicZDunkerAKIntrinsic disorder in cell-signaling and cancer-associated proteinsJ Mol Biol2002323357358410.1016/S0022-2836(02)00969-5<?supplied-pmid 12381310?>12381310 </plain></SENT>
</text></ref><ref id="CR52"><text><SENT sid="278" pm="."><plain>52.AgarwalRCell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agentsBiochem Pharmacol20006081051105910.1016/S0006-2952(00)00385-3<?supplied-pmid 11007941?>11007941 </plain></SENT>
</text></ref><ref id="CR53"><text><SENT sid="279" pm="."><plain>53.McArdlePAMirKAlmushatatASWallaceAMUnderwoodMAMcMillanDCSystemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancerUrol Int200677212712910.1159/000093905<?supplied-pmid 16888416?>16888416 </plain></SENT>
</text></ref><ref id="CR54"><text><SENT sid="280" pm="."><plain>54.BenharMEngelbergDLevitzkiAROS, stress-activated kinases and stress signaling in cancerEMBO Rep20023542042510.1093/embo-reports/kvf094<?supplied-pmid 11991946?>11991946 </plain></SENT>
</text></ref><ref id="CR55"><text><SENT sid="281" pm="."><plain>55.BodeAMDongZPost-translational modification of p53 in tumorigenesisNat Rev Cancer200441079380510.1038/nrc1455<?supplied-pmid 15510160?>15510160 </plain></SENT>
</text></ref><ref id="CR56"><text><SENT sid="282" pm="."><plain>56.de VisserKEEichtenACoussensLMParadoxical roles of the immune system during cancer developmentNat Rev Cancer200661243710.1038/nrc1782<?supplied-pmid 16397525?>16397525 </plain></SENT>
</text></ref><ref id="CR57"><text><SENT sid="283" pm="."><plain>57.HaldarSChintapalliJCroceCMTaxol induces bcl-2 phosphorylation and death of prostate cancer cellsCancer Res199656612531255<?supplied-pmid 8640809?>8640809 </plain></SENT>
</text></ref><ref id="CR58"><text><SENT sid="284" pm="."><plain>58.GurumurthySVasudevanKMRangnekarVMRegulation of apoptosis in prostate cancerCancer Metastasis Rev2001203–422524310.1023/A:1015583310759<?supplied-pmid 12085964?>12085964 </plain></SENT>
</text></ref><ref id="CR59"><text><SENT sid="285" pm="."><plain>59.SonnenscheinCOleaNPasanenMESotoAMNegative controls of cell proliferation: human prostate cancer cells and androgensCancer Res1989491334743481<?supplied-pmid 2731169?>2731169 </plain></SENT>
</text></ref><ref id="CR60"><text><SENT sid="286" pm="."><plain>60.ChungTDYuJJSpiottoMTBartkowskiMSimonsJWCharacterization of the role of IL-6 in the progression of prostate cancerProstate199938319920710.1002/(SICI)1097-0045(19990215)38:3&lt;199::AID-PROS4&gt;3.0.CO;2-H<?supplied-pmid 10068344?>10068344 </plain></SENT>
</text></ref><ref id="CR61"><text><SENT sid="287" pm="."><plain>61.PiercontiFMartiniMPintoFCenciTCapodimontiSCalarcoABassiPFLaroccaLMEpigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behaviorProstate201171331832510.1002/pros.21245<?supplied-pmid 20717995?>20717995 </plain></SENT>
</text></ref><ref id="CR62"><text><SENT sid="288" pm="."><plain>62.RamachandranKGopisettyGGordianENavarroLHaderCReisIMSchulzWASingalRMethylation-mediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic targetCancer Res20096941527153510.1158/0008-5472.CAN-08-3609<?supplied-pmid 19190346?>19190346 </plain></SENT>
</text></ref><ref id="CR63"><text><SENT sid="289" pm="."><plain>63.ChenWWChanDCDonaldCLillyMBKraftASPim family kinases enhance tumor growth of prostate cancer cellsMol Cancer Res20053844345110.1158/1541-7786.MCR-05-0007<?supplied-pmid 16123140?>16123140 </plain></SENT>
</text></ref><ref id="CR64"><text><SENT sid="290" pm="."><plain>64.MichaudDSDaughertySEBerndtSIPlatzEAYeagerMCrawfordEDHsingAHuangWYHayesRBGenetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancerCancer Res20066684525453010.1158/0008-5472.CAN-05-3987<?supplied-pmid 16618781?>16618781 </plain></SENT>
</text></ref><ref id="CR65"><text><SENT sid="291" pm="."><plain>65.KibelASSuarezBKBelaniJOhJWebsterRBrophy-EbbersMGuoCCatalonaWJPicusJGoodfellowPJCDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinomaCancer Res200363920332036<?supplied-pmid 12727815?>12727815 </plain></SENT>
</text></ref><ref id="CR66"><text><SENT sid="292" pm="."><plain>66.LobergRDDayLLHarwoodJYingCSt JohnLNGilesRNeeleyCKPientaKJCCL2 is a potent regulator of prostate cancer cell migration and proliferationNeoplasia20068757858610.1593/neo.06280<?supplied-pmid 16867220?>16867220 </plain></SENT>
</text></ref><ref id="CR67"><text><SENT sid="293" pm="."><plain>67.Matsushima-MiyagiTHatanoKNomuraMLi-WenLNishikawaTSagaKShimboTKanedaYTRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particlesClin Cancer Res201218226271628310.1158/1078-0432.CCR-12-1595<?supplied-pmid 23014529?>23014529 </plain></SENT>
</text></ref><ref id="CR68"><text><SENT sid="294" pm="."><plain>68.PrendergastGCActin’ up: RhoB in cancer and apoptosisNat Rev Cancer20011216216810.1038/35101096<?supplied-pmid 11905808?>11905808 </plain></SENT>
</text></ref><ref id="CR69"><text><SENT sid="295" pm="."><plain>69.BattistaMCGuimondMORobergeCDoueikAAFazliLGleaveMSabbaghRGallo-PayetNInhibition of DHCR24/seladin-1 impairs cellular homeostasis in prostate cancerProstate2010709921933<?supplied-pmid 20166102?>20166102 </plain></SENT>
</text></ref><ref id="CR70"><text><SENT sid="296" pm="."><plain>70.ChenXGongJZengHChenNHuangRHuangYNieLXuMXiaJZhaoFMengWZhouQMicroRNA145 targets BNIP3 and suppresses prostate cancer progressionCancer Res20107072728273810.1158/0008-5472.CAN-09-3718<?supplied-pmid 20332243?>20332243 </plain></SENT>
</text></ref><ref id="CR71"><text><SENT sid="297" pm="."><plain>71.RochesterMARiedemannJHellawellGOBrewsterSFMacaulayVMSilencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancerCancer Gene Ther20051219010010.1038/sj.cgt.7700775<?supplied-pmid 15499378?>15499378 </plain></SENT>
</text></ref><ref id="CR72"><text><SENT sid="298" pm="."><plain>72.JalavaSEUrbanucciALatonenLWalteringKKSahuBJanneOASeppalaJLahdesmakiHTammelaTLVisakorpiTAndrogen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancerOncogene201231414460447110.1038/onc.2011.624<?supplied-pmid 22266859?>22266859 </plain></SENT>
</text></ref><ref id="CR73"><text><SENT sid="299" pm="."><plain>73.DayMLZhaoXWuSSwansonPEHumphreyPAPhorbol ester-induced apoptosis is accompanied by NGFI-A and c-fos activation in androgen-sensitive prostate cancer cellsCell Growth Differ199457735741<?supplied-pmid 7947388?>7947388 </plain></SENT>
</text></ref><ref id="CR74"><text><SENT sid="300" pm="."><plain>74.TaichmanRSCooperCKellerETPientaKJTaichmanNSMcCauleyLKUse of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to boneCancer Res200262618321837<?supplied-pmid 11912162?>11912162 </plain></SENT>
</text></ref><ref id="CR75"><text><SENT sid="301" pm="."><plain>75.ObinataDTakayamaKUranoTMurataTIkedaKHorie-InoueKOuchiYTakahashiSInoueSARFGAP3, an androgen target gene, promotes prostate cancer cell proliferation and migrationInt J Cancer2012130102240224810.1002/ijc.26224<?supplied-pmid 21647875?>21647875 </plain></SENT>
</text></ref><ref id="CR76"><text><SENT sid="302" pm="."><plain>76.QiuLXLiRTZhangJBZhongWZBaiJLLiuBRZhengMHQianXPThe E-cadherin (CDH1)–160 C/A polymorphism and prostate cancer risk: a meta-analysisEur J Hum Genet200917224424910.1038/ejhg.2008.157<?supplied-pmid 18781193?>18781193 </plain></SENT>
</text></ref><ref id="CR77"><text><SENT sid="303" pm="."><plain>77.LuSLeeJReveloMWangXDongZSmad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude miceClin Cancer Res200713195692570210.1158/1078-0432.CCR-07-1078<?supplied-pmid 17908958?>17908958 </plain></SENT>
</text></ref><ref id="CR78"><text><SENT sid="304" pm="."><plain>78.ProchownikEVEagle GroveLDeublerDZhuXLStephensonRARohrLRYinXBrothmanARCommonly occurring loss and mutation of the MXI1 gene in prostate cancerGenes Chromosomes Cancer199822429530410.1002/(SICI)1098-2264(199808)22:4&lt;295::AID-GCC5&gt;3.0.CO;2-Q<?supplied-pmid 9669667?>9669667 </plain></SENT>
</text></ref><ref id="CR79"><text><SENT sid="305" pm="."><plain>79.Lehen′kyiVFlourakisMSkrymaRPrevarskayaNTRPV6 channel controls prostate cancer cell proliferation via Ca(2+)/NFAT-dependent pathwaysOncogene200726527380738510.1038/sj.onc.1210545<?supplied-pmid 17533368?>17533368 </plain></SENT>
</text></ref><ref id="CR80"><text><SENT sid="306" pm="."><plain>80.SankpalUTGoodisonSAbdelrahimMBashaRTargeting Sp1 transcription factors in prostate cancer therapyMed Chem20117551852510.2174/157340611796799203<?supplied-pmid 22022994?>22022994 </plain></SENT>
</text></ref><ref id="CR81"><text><SENT sid="307" pm="."><plain>81.ThebaultSFlourakisMVanoverbergheKVandermoereFRoudbarakiMLehen’kyiVSlomiannyCBeckBMariotPBonnalJLMauroyBShubaYCapiodTSkrymaRPrevarskayaNDifferential role of transient receptor potential channels in Ca2+ entry and proliferation of prostate cancer epithelial cellsCancer Res20066642038204710.1158/0008-5472.CAN-05-0376<?supplied-pmid 16489003?>16489003 </plain></SENT>
</text></ref><ref id="CR82"><text><SENT sid="308" pm="."><plain>82.MoltzahnFOlshenABBaehnerLPeekAFongLStopplerHSimkoJHiltonJFCarrollPBlellochRMicrofluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patientsCancer Res201171255056010.1158/0008-5472.CAN-10-1229<?supplied-pmid 21098088?>21098088 </plain></SENT>
</text></ref><ref id="CR83"><text><SENT sid="309" pm="."><plain>83.BonciDCoppolaVMusumeciMAddarioAGiuffridaRMemeoLD’UrsoLPagliucaABiffoniMLabbayeCBartucciMMutoGPeschleCDe MariaRThe miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activitiesNat Med200814111271127710.1038/nm.1880<?supplied-pmid 18931683?>18931683 </plain></SENT>
</text></ref><ref id="CR84"><text><SENT sid="310" pm="."><plain>84.KongDLiYWangZBanerjeeSAhmadAKimHRSarkarFHmiR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cellsStem Cells20092781712172110.1002/stem.101<?supplied-pmid 19544444?>19544444 </plain></SENT>
</text></ref><ref id="CR85"><text><SENT sid="311" pm="."><plain>85.RobinsonMDMcCarthyDJSmythGKedgeR: a Bioconductor package for differential expression analysis of digital gene expression dataBioinformatics201026113914010.1093/bioinformatics/btp616<?supplied-pmid 19910308?>19910308 </plain></SENT>
</text></ref><ref id="CR86"><text><SENT sid="312" pm="."><plain>86.ShyamsundarRKimYHHigginsJPMontgomeryKJordenMSethuramanAvan de RijnMBotsteinDBrownPOPollackJRA DNA microarray survey of gene expression in normal human tissuesGenome Biol200563R2210.1186/gb-2005-6-3-r22<?supplied-pmid 15774023?>15774023 </plain></SENT>
</text></ref><ref id="CR87"><text><SENT sid="313" pm="."><plain>87.LaTulippeESatagopanJSmithAScherHScardinoPReuterVGeraldWLComprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic diseaseCancer Res2002621544994506<?supplied-pmid 12154061?>12154061 </plain></SENT>
</text></ref><ref id="CR88"><text><SENT sid="314" pm="."><plain>88.TavazoieSHughesJDCampbellMJChoRJChurchGMSystematic determination of genetic network architectureNat Genet199922328128510.1038/10343<?supplied-pmid 10391217?>10391217 </plain></SENT>
</text></ref><ref id="CR89"><text><SENT sid="315" pm="."><plain>89.JonesSZhangXParsonsDWLinJCLearyRJAngenendtPMankooPCarterHKamiyamaHJimenoAHongSMFuBLinMTCalhounESKamiyamaMWalterKNikolskayaTNikolskyYHartiganJSmithDRHidalgoMLeachSDKleinAPJaffeeEMGogginsMMaitraAIacobuzio-DonahueCEshlemanJRKernSEHrubanRHCore signaling pathways in human pancreatic cancers revealed by global genomic analysesScience200832158971801180610.1126/science.1164368<?supplied-pmid 18772397?>18772397 </plain></SENT>
</text></ref><ref id="CR90"><text><SENT sid="316" pm="."><plain>90.LoweSWLinAWApoptosis in cancerCarcinogenesis200021348549510.1093/carcin/21.3.485<?supplied-pmid 10688869?>10688869 </plain></SENT>
</text></ref><ref id="CR91"><text><SENT sid="317" pm="."><plain>91.RothJANguyenDLawrenceDDKempBLCarrascoCHFersonDZHongWKKomakiRLeeJJNesbittJCPistersKMPutnamJBScheaRShinDMWalshGLDolormenteMMHanCIMartinFDYenNXuKStephensLCMcDonnellTJMukhopadhyayTCaiDRetrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancerNat Med19962998599110.1038/nm0996-985<?supplied-pmid 8782455?>8782455 </plain></SENT>
</text></ref><ref id="CR92"><text><SENT sid="318" pm="."><plain>92.BediAPasrichaPJAkhtarAJBarberJPBediGCGiardielloFMZehnbauerBAHamiltonSRJonesRJInhibition of apoptosis during development of colorectal cancerCancer Res199555918111816<?supplied-pmid 7728743?>7728743 </plain></SENT>
</text></ref><ref id="CR93"><text><SENT sid="319" pm="."><plain>93.HowellSBResistance to apoptosis in prostate cancer cellsMol Urol200043225229<?supplied-pmid 11062378?>11062378 </plain></SENT>
</text></ref><ref id="CR94"><text><SENT sid="320" pm="."><plain>94.LockshinRAZakeriZCell death in health and diseaseJ Cell Mol Med20071161214122410.1111/j.1582-4934.2007.00150.x<?supplied-pmid 18031301?>18031301 </plain></SENT>
</text></ref><ref id="CR95"><text><SENT sid="321" pm="."><plain>95.HanahanDWeinbergRAHallmarks of cancer: the next generationCell2011144564667410.1016/j.cell.2011.02.013<?supplied-pmid 21376230?>21376230 </plain></SENT>
</text></ref><ref id="CR96"><text><SENT sid="322" pm="."><plain>96.HanahanDWeinbergRAThe hallmarks of cancerCell20001001577010.1016/S0092-8674(00)81683-9<?supplied-pmid 10647931?>10647931 </plain></SENT>
</text></ref><ref id="CR97"><text><SENT sid="323" pm="."><plain>97.FuldaSGormanAMHoriOSamaliACellular stress responses: cell survival and cell deathInt J Cell Biol20102010214074<?supplied-pmid 20182529?>20182529 </plain></SENT>
</text></ref><ref id="CR98"><text><SENT sid="324" pm="."><plain>98.Abate-ShenCShenMMMolecular genetics of prostate cancerGenes Dev200014192410243410.1101/gad.819500<?supplied-pmid 11018010?>11018010 </plain></SENT>
</text></ref><ref id="CR99"><text><SENT sid="325" pm="."><plain>99.GrauerLSLawlerKDMarignacJLKumarAGoelASWolfertRLIdentification, purification, and subcellular localization of prostate-specific membrane antigen PSM’ protein in the LNCaP prostatic carcinoma cell lineCancer Res1998582147874789<?supplied-pmid 9809977?>9809977 </plain></SENT>
</text></ref><ref id="CR100"><text><SENT sid="326" pm="."><plain>100.ThiebautFTsuruoTHamadaHGottesmanMMPastanIWillinghamMCCellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissuesProc Natl Acad Sci U S A198784217735773810.1073/pnas.84.21.7735<?supplied-pmid 2444983?>2444983 </plain></SENT>
</text></ref><ref id="CR101"><text><SENT sid="327" pm="."><plain>101.HuRDunnTAWeiSIsharwalSVeltriRWHumphreysEHanMPartinAWVessellaRLIsaacsWBBovaGSLuoJLigand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancerCancer Res2009691162210.1158/0008-5472.CAN-08-2764<?supplied-pmid 19117982?>19117982 </plain></SENT>
</text></ref><ref id="CR102"><text><SENT sid="328" pm="."><plain>102.ShenHLentschABProgressive dysregulation of transcription factors NF-kappa B and STAT1 in prostate cancer cells causes proangiogenic production of CXC chemokinesAm J Physiol Cell Physiol20042864C840C84710.1152/ajpcell.00335.2003<?supplied-pmid 14656722?>14656722 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
